| Literature DB >> 21298649 |
Chandrasekar Palaniswamy1, Arunabh Sekhri, Wilbert S Aronow, Ankur Kalra, Stephen J Peterson.
Abstract
Vitamin K is required for the activity of various biologically active proteins in our body. Apart from clotting factors, vitamin K-dependent proteins include regulatory proteins like protein C, protein S, protein Z, osteocalcin, growth arrest-specific gene 6 protein, and matrix Gla protein. Glutamic acid residues in matrix Gla protein are γ-carboxylated by vitamin K-dependent γ-carboxylase, which enables it to inhibit calcification. Warfarin, being a vitamin K antagonist, inhibits this process, and has been associated with calcification in various animal and human studies. Though no specific guidelines are currently available to prevent or treat this less-recognized side effect, discontinuing warfarin and using an alternative anticoagulant seems to be a reasonable option. Newer anticoagulants such as dabigatran and rivaroxaban offer promise as future therapeutic options in such cases. Drugs including statins, alendronate, osteoprotegerin, and vitamin K are currently under study as therapies to prevent or treat warfarin-associated calcification.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21298649 PMCID: PMC6652734 DOI: 10.1002/clc.20865
Source DB: PubMed Journal: Clin Cardiol ISSN: 0160-9289 Impact factor: 2.882